巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    SCYNEXIS

    SCYX
    1.880
    0.030
    1.62%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・SCYNEXIS - 延遲價格・最後更新於 01/07 12:14
    最高位
    1.900
    最低位
    1.870
    開市價
    --
    前收市價
    1.850
    成交量(千)
    1.05
    成交額(百萬)
    0.02
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    61.25
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    8.100 - 1.700
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    SCYNEXIS
    證券代碼
    SCYX.US
    所屬板塊
    Drug Manufacturers - Specialty & Generic
    公司業務
    SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. It is engaged in developing a lead product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains.
    發行量
    20630750
    公司總部
    1 Evertrust Plaza, 13th Floor
    公司網址
    https://www.scynexis.com
    公司電郵
    investorrelations@scynexis.com
    公司電話
    +1 201 884-5485
    暫無內容

    關於

    SCYNEXIS(SCYX.US)所屬的行業板塊為Drug Manufacturers - Specialty & Generic。
    SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. It is engaged in developing a lead product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains.
    詳細公司背景可參考: https://www.scynexis.com